Revance Therapeutics, Inc. (RVNC)

Market Cap	404.92M
Revenue (ttm)	256.95M
Net Income (ttm)	-184.44M
Shares Out	104.90M
EPS (ttm)	-1.91
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	135,500
Open	3.770
Previous Close	3.800
Day's Range	3.760 - 3.860
52-Week Range	2.300 - 9.750
Beta	0.95
Analysts	Buy
Price Target	10.23 (+165.03%)
Earnings Date	Nov 7, 2024

About RVNC

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Ph...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 6, 2014
• Employees: 597
• Stock Exchange: NASDAQ
• Ticker Symbol: RVNC
• Website: https://www.revance.com

Financial Performance

In 2023, Revance Therapeutics's revenue was $234.04 million, an increase of 76.55% compared to the previous year's $132.57 million. Losses were -$323.99 million, -9.10% less than in 2022.

Analyst Forecast

According to 10 analysts, the average rating for RVNC stock is "Buy." The 12-month stock price forecast is $10.23, which is an increase of 165.03% from the latest price.

Price Target

$10.23

(165.03% upside)

Analyst Consensus: Buy